Enhanced Multicenter Dietary Portfolio Study (EDP8)

April 25, 2017 updated by: Unity Health Toronto

The Effect of an Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk in High Risk Individuals.

"Is it possible to recruit and retain up to 200 participants in a Randomize Control Trial (RCT) of high impact lifestyle approach of diet and exercise designed to significantly reduce cardiovascular events in middle-aged and older men and women at high risk of such events?" To address this question, we propose a pilot study of 3 years in duration: 1 year recruitment and randomization, a full year of intervention for all recruited participants, and the last 6 months to assess the one year data and prepare and submit the full trial application, informed by the pilot study outcomes in terms of retention rate. The pilot will then continue on for the full 9 years of intervention and be rolled into the main study involving additional Canadian centers and collaborating international centers in the US, Britain, Europe, Australia, New Zealand, India, and South Africa.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

There is a major need for a large RCT to demonstrate the effect of lifestyle modification (diet and exercise) on cardiovascular disease (CVD) outcomes. The pilot study will demonstrate the feasibility as a prerequisite for continuing on to the large RCT. Large RCT: This trial will test the effect of a high impact dietary approach combining foods with functional effects, including LDL-cholesterol (LDL-C) and blood pressure (BP) reduction, together with an exercise program which has been associated with reduction in carotid atheroma assessed by MRI. The combined approach will have a more significant effect on CVD risk factors than previous trials and will be compared with a high cereal fibre diet and exercise advice, consistent with good clinical practice, in a randomized parallel trial of 9 years duration. ~6,000 high risk participants will be recruited comprising individuals with 1) type 2 diabetes, 2) post myocardial infarction (MI), and 3) Statin intolerant individuals. The primary outcome will be CVD event (MI, and stroke, fatal and non-fatal) (1). We believe we will achieve a 20% reduction in CVD events with ~10% related to diet reflected in reduction in traditional risk factors (LDL-C, BP) and 10% to exercise and increased cardiovascular fitness at year 9.

Pilot Study: We therefore propose to undertake a 1 year pilot study with 200 participants to demonstrate feasibility: 1) Successful recruitment (200 participants/year) and 2) retention (>90%)

Background: We have demonstrated the specific CVD reducing potential of the proposed components of our dietary intervention in a series of CIHR funded studies. The core dietary components (dietary portfolio of FDA approved cholesterol-lowering foods) in our recent CIHR-funded trial reduced LDL-C by 13-14% (JAMA 2011) with reductions also in diastolic blood pressure over 6 months. The CVD risk score was reduced by ~10% on the treatment. This approach will be combined with increased levels of monounsaturated fat (MUFA) which in a further CIHR-funded portfolio study raised HDL-C and reduced the total:HDL-C ratio (CMAJ 2010) resulting in an ~11% CVD risk score reduction on the high MUFA compared to the low MUFA portfolio. Low glycemic index foods will be selected which in our CIHR-funded trial in type 2 diabetes increased HDL-C and reduced HbA1c, the total:HDL-C ratio (JAMA 2008) and, with the added emphasis on legumes (dried peas, beans, lentils), significantly reduced BP leading to a CVD risk score reduction of ~5% (Arch Intern Med 2012). We consider this dietary package to have major potential in CVD risk reduction with a possible reduction in relative risk of 24% in the absence of negative or positive interactions.

The physical activity/exercise intervention is the end-product of a 25 year cumulative experience of investigators of the Quebec Heart and Lung Institute regarding physical activity/exercise prescriptions to various types of individuals/patients. Our program has also been recently tested in high risk patients with documented coronary artery disease managed by coronary artery bypass graft procedure (with/without type 2 diabetes). Unpublished preliminary results from this latter intervention in high risk patients indicate that our program not only induces substantial improvements in the CVD risk factor profile beyond clinical guidelines-aligned with optimal pharmacotherapy but that such an intervention appears to induce a significant reduction in carotid artery atherosclerosis assessed by magnetic resonance imaging. The latest meta-analysis estimated that only 150 min/week of moderate exercise reduced CHD risk by 14%. Our Laval program with a 420 min/wk of moderate exercise plus additional structured exercise would therefore also reduce CVD risk by at least 14% (or as much as 39% if the relationship between exercise time and CVD risk reduction were linear). The program aims to reduce sedentary behavior. It is safe and affordable in clinical practice. At a cost of about $900 per patient in the first year where the major training takes place, it is considerably less expensive than the DPP, DPS and Look AHEAD trials.

The research questions are therefore:

  1. What is the feasibility in terms of recruitment and retention of implementing a high impact diet and physical activity/exercise program for CVD prevention in high risk or statin-intolerant individuals?
  2. Based on the observed retention in the pilot study, the required recruitment for the large trial can be refined, if necessary.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • Healthy Heart Lipid Clinic, St. Paul's Hospital
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3T 6C5
        • Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba
    • Ontario
      • Toronto, Ontario, Canada, M5C 2T2
        • Risk Factor Modification Centre, St. Michael's Hospital
    • Quebec
      • Quebec City, Quebec, Canada, G1V 4G2
        • Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

A) Inclusion Criteria:

Eligible participants will be:

  1. men, over 50
  2. postmenopausal women, over 60 or
  3. postmenopausal women under 60 with a family history of hypercholesterolemia and 1 CVD risk factor.

Participants will have the following characteristics:

  • BMI 25-40 kg/m2 with body weight that has remained constant (within ±3%) over the last 3 months preceding the onset of the study

  • Plus at least 1 of the following 3 criteria:

    1. have type 2 diabetes with one of the following:

      • raised LDL-C(in accordance with the 2012 Canadian Cardiovascular Society Guidelines)
      • raised BP (> 130/80mmHg), or
      • active smoking;
    2. be non-diabetic subjects post MI or post percutaneous coronary intervention (angioplasty) on statin therapy; and
    3. have a modified Framingham risk score >20% (CCS 2012) and are unable (intolerant) or unwilling to take statin drugs.

B) Exclusion Criteria:

Individuals with the following conditions will be excluded:

  • cardiovascular disease that precludes exercise e.g.

    • recent stroke or
    • myocardial infarction, or

  • cardiac condition that compromises normal function

    • mitral valve disease,
    • heart failure--grades 2-4 (New York Heart Association classification),
    • severe angina or
    • other conditions preventing exercise,

  • secondary causes of hypercholesterolemia

    • hypothyroidism, (unless treated and on a stable dose of L-thyroxine)
    • renal or liver disease
  • uncontrolled blood pressure
  • major disability

  • disorder requiring continuous medical attention and treatment:

    • chronic heart failure,
    • liver disease,
    • renal failure or
    • cancer (except non-melanoma skin cancer--basal cell, squamous cell),
  • chronic infections (bacterial or viral)
  • chronic inflammatory diseases (e.g. lupus, ulcerative colitis)
  • other autoimmune diseases
  • major surgery <6 months prior to randomization
  • alcohol consumption >2 drinks/d.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Enhanced Portfolio plus structured exercise
Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
Behavioral: Enhanced portfolio plus structured exercise

Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).

Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute.

Other Names:
  • Dietary Portfolio of cholesterol-lowering foods
  • Laval exercise program
Active Comparator: High fiber diet plus routine exercise
A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
Behavioral: High fiber diet plus routine exercise

Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.

Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility measured by recruitment and retention rates
Time Frame: 1 year in a 9 year study

Pilot study: Recruitment and retention rates will establish the feasibility of proceeding to the large RCT ie the 9 year intervention study.

Long term study (9 years intervention): Non-fatal MI, non-fatal stroke and CV mortality as defined by MACE.
1 year in a 9 year study

Secondary Outcome Measures

Outcome Measure
Time Frame
Serum lipids: total cholesterol, LDL-chol, HDL-chol and Triglycerides
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and 12
At months -3, -2, -1 and then at months 0, 3, 6 and 12
C-reactive protein
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and 12
At months -3, -2, -1 and then at months 0, 3, 6 and 12
Hemoglobin A1c
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and 12
At months -3, -2, -1 and then at months 0, 3, 6 and 12
Glucose
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and 12
At months -3, -2, -1 and then at months 0, 3, 6 and 12
Blood Pressure
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and 12
At months -3, -2, -1 and then at months 0, 3, 6 and 12
treadmill testing
Time Frame: At months 0 and 12
At months 0 and 12
diet history
Time Frame: At months -3, -2, -1 and then at months 0, 3, 6 and12
At months -3, -2, -1 and then at months 0, 3, 6 and12
Pedometer records
Time Frame: At months 0, 2, 4, 6, 8, 10 and 12
At months 0, 2, 4, 6, 8, 10 and 12
Exercise history
Time Frame: At months 0, 3, 6, and 12
At months 0, 3, 6, and 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Unity Health Toronto

Collaborators

University of Manitoba
University of British Columbia
Canadian Institutes of Health Research (CIHR)
University of Toronto
Laval University

Investigators

  • Study Director: Jiri Frohilich, MD, University of British Columbia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Primary Completion (Actual)

October 7, 2014

Study Completion (Actual)

October 7, 2014

Study Registration Dates

First Submitted

September 23, 2013

First Submitted That Met QC Criteria

September 30, 2013

First Posted (Estimate)

October 1, 2013

Study Record Updates

Last Update Posted (Actual)

April 26, 2017

Last Update Submitted That Met QC Criteria

April 25, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REB 13-188
  • FRN 130278 (Other Grant/Funding Number: Canadian Institutes of Health Research (CIHR))

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Enhanced portfolio plus structured exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe